CliffBio
biologic

Spevigo

spesolimab-sbzo

Loss of exclusivitySeptember 2034projected — 12-year biologic exclusivity estimate
CompanyLEO Pharma A/S

Drug detail

Brand nameSpevigo
Active ingredientspesolimab-sbzo
Strength450MG/7.5ML (60MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2022
Marketing statusRx

More from LEO Pharma A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.